Wells Fargo lowered the firm’s price target on Insulet to $240 from $330 and keeps an Overweight rating on the shares. Insulet reported a strong beat and raise quarter, as well as a strong preliminary outlook for 2024, the analyst tells investors in a research note. The firm believes Insulet’s unique pay-as-you-go model and form factor justify a premium to the peer group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PODD:
- Early notable gainers among liquid option names on November 3rd
- Insulet price target lowered to $175 from $355 at Canaccord
- Insulet price target lowered to $180 from $219 at Baird
- Insulet raises FY23 revenue growth view to 26%-27% form 22%-25%
- Insulet sees Q4 revenue growth 22%-25%, consensus $456.14M